| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 50 | 2021 | 463 | 12.240 |
Why?
|
| Heart Arrest | 27 | 2020 | 320 | 6.020 |
Why?
|
| Myocardial Infarction | 30 | 2021 | 1121 | 5.190 |
Why?
|
| Hospitals | 18 | 2021 | 468 | 4.780 |
Why?
|
| Cardiopulmonary Resuscitation | 22 | 2022 | 233 | 4.640 |
Why?
|
| Coronary Artery Disease | 21 | 2021 | 701 | 4.580 |
Why?
|
| United States Department of Veterans Affairs | 19 | 2020 | 498 | 4.390 |
Why?
|
| Registries | 46 | 2022 | 1824 | 3.420 |
Why?
|
| Hospitalization | 22 | 2021 | 1678 | 2.730 |
Why?
|
| Veterans | 14 | 2020 | 906 | 2.600 |
Why?
|
| Practice Patterns, Physicians' | 13 | 2021 | 1214 | 2.560 |
Why?
|
| Coronary Angiography | 10 | 2018 | 334 | 2.510 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 6 | 2021 | 93 | 2.420 |
Why?
|
| Cardiovascular Diseases | 13 | 2021 | 1711 | 2.390 |
Why?
|
| Guideline Adherence | 10 | 2021 | 528 | 2.280 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2020 | 63 | 2.130 |
Why?
|
| Patient Selection | 11 | 2020 | 694 | 2.070 |
Why?
|
| Aged | 90 | 2021 | 20109 | 2.050 |
Why?
|
| United States | 72 | 2022 | 12329 | 2.040 |
Why?
|
| Platelet Aggregation Inhibitors | 8 | 2021 | 375 | 2.000 |
Why?
|
| Coronary Artery Bypass | 6 | 2021 | 271 | 1.900 |
Why?
|
| Health Status | 8 | 2020 | 773 | 1.840 |
Why?
|
| Cardiology | 9 | 2022 | 319 | 1.830 |
Why?
|
| Hospitals, Veterans | 7 | 2020 | 277 | 1.810 |
Why?
|
| Exercise Test | 4 | 2021 | 598 | 1.700 |
Why?
|
| Hospital Costs | 6 | 2020 | 124 | 1.690 |
Why?
|
| Middle Aged | 83 | 2021 | 28753 | 1.670 |
Why?
|
| Hypothermia, Induced | 4 | 2021 | 118 | 1.640 |
Why?
|
| Hospital Mortality | 19 | 2021 | 848 | 1.590 |
Why?
|
| Time Factors | 42 | 2021 | 7060 | 1.530 |
Why?
|
| Aortic Valve Stenosis | 7 | 2022 | 286 | 1.530 |
Why?
|
| Risk Assessment | 22 | 2021 | 3147 | 1.520 |
Why?
|
| Humans | 156 | 2022 | 113846 | 1.520 |
Why?
|
| Quality Indicators, Health Care | 8 | 2019 | 307 | 1.480 |
Why?
|
| Myocardial Ischemia | 4 | 2018 | 309 | 1.470 |
Why?
|
| Angina, Stable | 3 | 2019 | 15 | 1.410 |
Why?
|
| Male | 106 | 2021 | 60993 | 1.400 |
Why?
|
| Ventricular Fibrillation | 5 | 2018 | 61 | 1.400 |
Why?
|
| Healthcare Disparities | 6 | 2021 | 465 | 1.380 |
Why?
|
| Female | 103 | 2021 | 63035 | 1.350 |
Why?
|
| Treatment Outcome | 43 | 2022 | 9002 | 1.340 |
Why?
|
| Risk Factors | 45 | 2022 | 9050 | 1.330 |
Why?
|
| Patient Identification Systems | 3 | 2016 | 19 | 1.260 |
Why?
|
| Myocardial Perfusion Imaging | 3 | 2018 | 49 | 1.260 |
Why?
|
| Quality Improvement | 10 | 2021 | 934 | 1.230 |
Why?
|
| Tachycardia, Ventricular | 5 | 2018 | 179 | 1.220 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2018 | 232 | 1.200 |
Why?
|
| Electric Countershock | 6 | 2018 | 130 | 1.160 |
Why?
|
| Angina Pectoris | 3 | 2015 | 78 | 1.150 |
Why?
|
| Retrospective Studies | 45 | 2021 | 11340 | 1.150 |
Why?
|
| Hydroxychloroquine | 2 | 2021 | 58 | 1.080 |
Why?
|
| Decision Support Techniques | 7 | 2020 | 388 | 1.060 |
Why?
|
| Angioplasty, Balloon, Coronary | 4 | 2015 | 172 | 1.060 |
Why?
|
| Defibrillators, Implantable | 2 | 2020 | 401 | 1.060 |
Why?
|
| Guidelines as Topic | 3 | 2021 | 286 | 1.020 |
Why?
|
| Aged, 80 and over | 32 | 2021 | 6796 | 1.020 |
Why?
|
| Radial Artery | 5 | 2017 | 64 | 1.010 |
Why?
|
| ST Elevation Myocardial Infarction | 6 | 2021 | 42 | 0.990 |
Why?
|
| Drug-Eluting Stents | 3 | 2017 | 71 | 0.960 |
Why?
|
| Heart Failure | 6 | 2021 | 1899 | 0.950 |
Why?
|
| Transcatheter Aortic Valve Replacement | 5 | 2022 | 136 | 0.950 |
Why?
|
| Practice Guidelines as Topic | 10 | 2019 | 1529 | 0.940 |
Why?
|
| Coronary Disease | 4 | 2020 | 469 | 0.930 |
Why?
|
| Patient Reported Outcome Measures | 2 | 2020 | 211 | 0.900 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2020 | 20 | 0.890 |
Why?
|
| Rural Health | 1 | 2021 | 96 | 0.870 |
Why?
|
| Patient Discharge | 10 | 2021 | 743 | 0.870 |
Why?
|
| Stroke | 10 | 2021 | 930 | 0.860 |
Why?
|
| Acute Coronary Syndrome | 5 | 2019 | 234 | 0.860 |
Why?
|
| Coronary Stenosis | 2 | 2017 | 47 | 0.850 |
Why?
|
| SARS Virus | 1 | 2020 | 14 | 0.840 |
Why?
|
| Length of Stay | 9 | 2021 | 1062 | 0.830 |
Why?
|
| Program Evaluation | 6 | 2021 | 863 | 0.830 |
Why?
|
| Coronavirus | 1 | 2020 | 30 | 0.820 |
Why?
|
| Unnecessary Procedures | 3 | 2015 | 48 | 0.810 |
Why?
|
| Odds Ratio | 12 | 2021 | 1064 | 0.800 |
Why?
|
| Smartphone | 1 | 2020 | 62 | 0.800 |
Why?
|
| Preoperative Care | 2 | 2021 | 339 | 0.800 |
Why?
|
| Time-to-Treatment | 6 | 2020 | 153 | 0.790 |
Why?
|
| Emergency Medical Services | 6 | 2022 | 521 | 0.790 |
Why?
|
| Preventive Health Services | 1 | 2021 | 140 | 0.780 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 388 | 0.770 |
Why?
|
| Airway Management | 1 | 2019 | 44 | 0.760 |
Why?
|
| Predictive Value of Tests | 12 | 2020 | 2025 | 0.760 |
Why?
|
| Insurance, Health | 2 | 2021 | 250 | 0.760 |
Why?
|
| Antirheumatic Agents | 1 | 2021 | 249 | 0.760 |
Why?
|
| Quality of Health Care | 5 | 2016 | 643 | 0.740 |
Why?
|
| Echocardiography, Doppler | 2 | 2021 | 128 | 0.730 |
Why?
|
| American Heart Association | 9 | 2022 | 285 | 0.710 |
Why?
|
| Physical Fitness | 1 | 2019 | 192 | 0.710 |
Why?
|
| Pneumonia, Viral | 5 | 2021 | 354 | 0.700 |
Why?
|
| Cardiovascular Agents | 4 | 2018 | 127 | 0.700 |
Why?
|
| Heart Diseases | 2 | 2018 | 368 | 0.690 |
Why?
|
| Follow-Up Studies | 13 | 2021 | 4906 | 0.690 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2021 | 313 | 0.680 |
Why?
|
| Transportation of Patients | 2 | 2018 | 52 | 0.680 |
Why?
|
| Natural Language Processing | 1 | 2018 | 108 | 0.670 |
Why?
|
| Elective Surgical Procedures | 4 | 2018 | 157 | 0.660 |
Why?
|
| Prasugrel Hydrochloride | 1 | 2016 | 17 | 0.660 |
Why?
|
| Resuscitation | 2 | 2019 | 293 | 0.660 |
Why?
|
| Health Care Costs | 2 | 2019 | 395 | 0.650 |
Why?
|
| Survival Rate | 9 | 2020 | 1854 | 0.650 |
Why?
|
| Aortic Valve | 4 | 2022 | 449 | 0.650 |
Why?
|
| Incidence | 11 | 2021 | 2470 | 0.640 |
Why?
|
| Hemorrhage | 10 | 2021 | 577 | 0.630 |
Why?
|
| Medicare | 9 | 2021 | 606 | 0.630 |
Why?
|
| Logistic Models | 12 | 2020 | 2053 | 0.620 |
Why?
|
| Disease Management | 2 | 2019 | 606 | 0.620 |
Why?
|
| Mortality | 7 | 2021 | 328 | 0.610 |
Why?
|
| Patient Care Planning | 1 | 2016 | 166 | 0.610 |
Why?
|
| Surgical Procedures, Operative | 1 | 2018 | 224 | 0.600 |
Why?
|
| Assisted Circulation | 1 | 2015 | 25 | 0.600 |
Why?
|
| Medication Errors | 1 | 2016 | 97 | 0.600 |
Why?
|
| Cohort Studies | 15 | 2021 | 5011 | 0.590 |
Why?
|
| Aspirin | 5 | 2021 | 317 | 0.590 |
Why?
|
| Comorbidity | 10 | 2021 | 1601 | 0.590 |
Why?
|
| Electrocardiography | 4 | 2021 | 661 | 0.580 |
Why?
|
| Delivery of Health Care | 3 | 2021 | 695 | 0.580 |
Why?
|
| Resuscitation Orders | 3 | 2020 | 41 | 0.560 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 339 | 0.560 |
Why?
|
| Chi-Square Distribution | 8 | 2018 | 572 | 0.550 |
Why?
|
| Washington | 6 | 2018 | 125 | 0.540 |
Why?
|
| Atrial Fibrillation | 5 | 2021 | 359 | 0.540 |
Why?
|
| Risk Adjustment | 4 | 2020 | 78 | 0.540 |
Why?
|
| Health Services Accessibility | 3 | 2018 | 777 | 0.530 |
Why?
|
| Postoperative Complications | 4 | 2019 | 2116 | 0.530 |
Why?
|
| Myocardial Reperfusion | 1 | 2013 | 75 | 0.520 |
Why?
|
| Myocardial Revascularization | 3 | 2019 | 98 | 0.520 |
Why?
|
| Periodicals as Topic | 1 | 2017 | 264 | 0.510 |
Why?
|
| Vascular Surgical Procedures | 2 | 2021 | 232 | 0.510 |
Why?
|
| Heart Valve Prosthesis Implantation | 4 | 2021 | 188 | 0.510 |
Why?
|
| Forecasting | 3 | 2020 | 399 | 0.510 |
Why?
|
| Anticoagulants | 4 | 2021 | 534 | 0.500 |
Why?
|
| Health Promotion | 1 | 2019 | 664 | 0.500 |
Why?
|
| Telemedicine | 1 | 2020 | 540 | 0.490 |
Why?
|
| Surveys and Questionnaires | 6 | 2021 | 4625 | 0.490 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 368 | 0.480 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2013 | 73 | 0.480 |
Why?
|
| Secondary Prevention | 4 | 2021 | 241 | 0.480 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 602 | 0.470 |
Why?
|
| Patient Readmission | 8 | 2019 | 621 | 0.460 |
Why?
|
| Health Services Needs and Demand | 1 | 2013 | 259 | 0.450 |
Why?
|
| Sleep Deprivation | 3 | 2019 | 176 | 0.450 |
Why?
|
| Communication Barriers | 2 | 2011 | 78 | 0.440 |
Why?
|
| Clinical Decision-Making | 5 | 2019 | 274 | 0.420 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2021 | 65 | 0.410 |
Why?
|
| Biomedical Research | 1 | 2016 | 609 | 0.410 |
Why?
|
| Hemofiltration | 1 | 2009 | 35 | 0.400 |
Why?
|
| Cardiology Service, Hospital | 2 | 2020 | 30 | 0.400 |
Why?
|
| Survival Analysis | 6 | 2019 | 1414 | 0.400 |
Why?
|
| Quality of Life | 3 | 2020 | 2136 | 0.390 |
Why?
|
| Medical Futility | 2 | 2019 | 22 | 0.390 |
Why?
|
| Shock, Cardiogenic | 3 | 2020 | 56 | 0.380 |
Why?
|
| Referral and Consultation | 3 | 2018 | 635 | 0.380 |
Why?
|
| Bundle-Branch Block | 2 | 2019 | 27 | 0.380 |
Why?
|
| Severity of Illness Index | 11 | 2021 | 2828 | 0.380 |
Why?
|
| Databases, Factual | 7 | 2019 | 1206 | 0.370 |
Why?
|
| Betacoronavirus | 3 | 2020 | 265 | 0.360 |
Why?
|
| Exercise | 1 | 2019 | 1718 | 0.360 |
Why?
|
| Cross-Sectional Studies | 8 | 2021 | 4275 | 0.350 |
Why?
|
| Centralized Hospital Services | 2 | 2018 | 5 | 0.350 |
Why?
|
| Cardiologists | 2 | 2018 | 40 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 595 | 0.340 |
Why?
|
| Sleep | 3 | 2019 | 710 | 0.340 |
Why?
|
| Intensive Care Units | 2 | 2021 | 585 | 0.330 |
Why?
|
| Emergency Service, Hospital | 2 | 2020 | 1755 | 0.330 |
Why?
|
| African Americans | 3 | 2017 | 1101 | 0.330 |
Why?
|
| Health Status Disparities | 2 | 2020 | 220 | 0.330 |
Why?
|
| Drug Utilization Review | 2 | 2016 | 62 | 0.320 |
Why?
|
| Depression | 1 | 2015 | 1129 | 0.310 |
Why?
|
| Prognosis | 5 | 2020 | 3544 | 0.310 |
Why?
|
| Intubation, Intratracheal | 2 | 2019 | 202 | 0.310 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2020 | 388 | 0.300 |
Why?
|
| Veterans Health | 2 | 2018 | 130 | 0.300 |
Why?
|
| Acute Kidney Injury | 3 | 2020 | 613 | 0.290 |
Why?
|
| Cost Savings | 3 | 2019 | 83 | 0.280 |
Why?
|
| Prospective Studies | 7 | 2022 | 6250 | 0.270 |
Why?
|
| Warfarin | 3 | 2022 | 138 | 0.270 |
Why?
|
| Adult | 16 | 2022 | 31979 | 0.260 |
Why?
|
| Liver Transplantation | 1 | 2010 | 718 | 0.260 |
Why?
|
| Ventricular Function, Left | 3 | 2021 | 489 | 0.250 |
Why?
|
| Reproducibility of Results | 4 | 2021 | 2905 | 0.250 |
Why?
|
| Emergency Medical Service Communication Systems | 2 | 2014 | 8 | 0.250 |
Why?
|
| Societies, Medical | 2 | 2017 | 768 | 0.240 |
Why?
|
| Data Accuracy | 1 | 2022 | 48 | 0.240 |
Why?
|
| Bed Occupancy | 1 | 2021 | 16 | 0.230 |
Why?
|
| Hospital Bed Capacity | 1 | 2021 | 23 | 0.230 |
Why?
|
| Patient Care Team | 2 | 2018 | 532 | 0.230 |
Why?
|
| Technology Transfer | 1 | 2021 | 15 | 0.230 |
Why?
|
| Medication Adherence | 3 | 2021 | 557 | 0.230 |
Why?
|
| Embolic Protection Devices | 1 | 2021 | 6 | 0.230 |
Why?
|
| Patient Outcome Assessment | 2 | 2021 | 124 | 0.220 |
Why?
|
| Insurance Carriers | 1 | 2021 | 8 | 0.220 |
Why?
|
| Diagnosis-Related Groups | 1 | 2020 | 40 | 0.220 |
Why?
|
| Adult Survivors of Child Abuse | 1 | 2021 | 18 | 0.220 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2021 | 42 | 0.220 |
Why?
|
| Pandemics | 4 | 2020 | 881 | 0.220 |
Why?
|
| Hospitals, Public | 1 | 2020 | 25 | 0.220 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2021 | 83 | 0.220 |
Why?
|
| Language | 2 | 2015 | 236 | 0.210 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 1136 | 0.210 |
Why?
|
| Heart Valve Prosthesis | 1 | 2022 | 130 | 0.210 |
Why?
|
| Aneurysm, Dissecting | 1 | 2021 | 89 | 0.210 |
Why?
|
| Hypertension | 3 | 2019 | 1185 | 0.210 |
Why?
|
| Cardiac Catheterization | 3 | 2019 | 550 | 0.210 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 1599 | 0.210 |
Why?
|
| Health Facility Size | 2 | 2017 | 14 | 0.200 |
Why?
|
| Electronic Health Records | 4 | 2021 | 670 | 0.200 |
Why?
|
| Chloroquine | 1 | 2020 | 65 | 0.200 |
Why?
|
| Recovery of Function | 3 | 2019 | 604 | 0.200 |
Why?
|
| Triage | 2 | 2021 | 217 | 0.200 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 147 | 0.200 |
Why?
|
| Inpatients | 2 | 2020 | 335 | 0.190 |
Why?
|
| Publishing | 1 | 2021 | 161 | 0.190 |
Why?
|
| Health Services Research | 2 | 2012 | 396 | 0.190 |
Why?
|
| Pulse | 1 | 2018 | 35 | 0.190 |
Why?
|
| Patient Safety | 3 | 2018 | 309 | 0.190 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 1141 | 0.190 |
Why?
|
| Thrombectomy | 1 | 2019 | 36 | 0.190 |
Why?
|
| Eligibility Determination | 1 | 2019 | 49 | 0.190 |
Why?
|
| Heart Injuries | 1 | 2018 | 30 | 0.190 |
Why?
|
| Coronary Occlusion | 1 | 2018 | 14 | 0.190 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 27 | 0.190 |
Why?
|
| Environment | 1 | 2021 | 400 | 0.190 |
Why?
|
| Life Style | 1 | 2021 | 441 | 0.190 |
Why?
|
| Pacemaker, Artificial | 1 | 2019 | 116 | 0.180 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 50 | 0.180 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 46 | 0.180 |
Why?
|
| Leukocyte Count | 1 | 2019 | 325 | 0.180 |
Why?
|
| Treatment Refusal | 1 | 2018 | 90 | 0.180 |
Why?
|
| Mitral Valve | 1 | 2019 | 107 | 0.180 |
Why?
|
| Research Design | 2 | 2021 | 913 | 0.180 |
Why?
|
| Drug Users | 1 | 2018 | 41 | 0.180 |
Why?
|
| Vascular System Injuries | 1 | 2018 | 56 | 0.180 |
Why?
|
| Administrative Claims, Healthcare | 1 | 2017 | 20 | 0.180 |
Why?
|
| Health Care Surveys | 2 | 2018 | 580 | 0.180 |
Why?
|
| Echocardiography, Stress | 1 | 2017 | 28 | 0.180 |
Why?
|
| Anesthesiology | 1 | 2017 | 32 | 0.180 |
Why?
|
| Subacute Care | 1 | 2018 | 63 | 0.180 |
Why?
|
| Prevalence | 4 | 2020 | 2407 | 0.170 |
Why?
|
| Documentation | 1 | 2019 | 161 | 0.170 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2016 | 231 | 0.170 |
Why?
|
| Inservice Training | 1 | 2018 | 111 | 0.170 |
Why?
|
| Efficiency, Organizational | 1 | 2018 | 136 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 2 | 2018 | 124 | 0.170 |
Why?
|
| Radiologists | 1 | 2017 | 29 | 0.170 |
Why?
|
| Behavior, Addictive | 1 | 2018 | 95 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2018 | 89 | 0.170 |
Why?
|
| Work Schedule Tolerance | 1 | 2017 | 48 | 0.170 |
Why?
|
| Early Diagnosis | 2 | 2015 | 251 | 0.170 |
Why?
|
| Obesity | 3 | 2021 | 2627 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2018 | 135 | 0.170 |
Why?
|
| Contrast Media | 1 | 2020 | 414 | 0.170 |
Why?
|
| Clinical Competence | 3 | 2019 | 913 | 0.170 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 112 | 0.170 |
Why?
|
| International Classification of Diseases | 1 | 2017 | 114 | 0.170 |
Why?
|
| Cardiac Rehabilitation | 1 | 2017 | 33 | 0.170 |
Why?
|
| Patient Admission | 1 | 2018 | 198 | 0.170 |
Why?
|
| Hemoglobins | 1 | 2019 | 298 | 0.160 |
Why?
|
| Hospitals, Teaching | 1 | 2017 | 112 | 0.160 |
Why?
|
| Catheterization, Peripheral | 1 | 2017 | 86 | 0.160 |
Why?
|
| Coronary Thrombosis | 1 | 2016 | 28 | 0.160 |
Why?
|
| Thoracic Surgery | 1 | 2017 | 120 | 0.160 |
Why?
|
| Thromboembolism | 1 | 2017 | 104 | 0.160 |
Why?
|
| Workload | 1 | 2017 | 134 | 0.160 |
Why?
|
| Crowdsourcing | 1 | 2016 | 14 | 0.160 |
Why?
|
| Off-Label Use | 1 | 2016 | 40 | 0.160 |
Why?
|
| Linear Models | 3 | 2017 | 909 | 0.160 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 216 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2016 | 368 | 0.160 |
Why?
|
| Contraindications | 1 | 2016 | 97 | 0.160 |
Why?
|
| Cerebrovascular Disorders | 1 | 2017 | 86 | 0.160 |
Why?
|
| Tuberculosis | 1 | 2019 | 228 | 0.160 |
Why?
|
| Drug Labeling | 1 | 2016 | 45 | 0.160 |
Why?
|
| Regression Analysis | 2 | 2017 | 1137 | 0.160 |
Why?
|
| Coronary Vessels | 1 | 2018 | 283 | 0.160 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2016 | 69 | 0.150 |
Why?
|
| Echocardiography | 4 | 2021 | 637 | 0.150 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2016 | 80 | 0.150 |
Why?
|
| Lipids | 1 | 2020 | 629 | 0.150 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2015 | 26 | 0.150 |
Why?
|
| Statistics as Topic | 1 | 2016 | 365 | 0.150 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 17 | 0.150 |
Why?
|
| Cell Phone | 1 | 2016 | 73 | 0.150 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 326 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2017 | 271 | 0.150 |
Why?
|
| Ethics, Research | 1 | 2015 | 34 | 0.140 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 463 | 0.140 |
Why?
|
| Costs and Cost Analysis | 2 | 2019 | 210 | 0.140 |
Why?
|
| Telephone | 1 | 2015 | 163 | 0.140 |
Why?
|
| Occupational Health | 1 | 2017 | 212 | 0.140 |
Why?
|
| Models, Organizational | 1 | 2015 | 159 | 0.140 |
Why?
|
| beta-Alanine | 1 | 2014 | 24 | 0.140 |
Why?
|
| Qualitative Research | 1 | 2018 | 781 | 0.140 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 83 | 0.140 |
Why?
|
| Burnout, Professional | 1 | 2019 | 279 | 0.140 |
Why?
|
| Andropause | 1 | 2013 | 9 | 0.140 |
Why?
|
| Antithrombins | 1 | 2014 | 57 | 0.130 |
Why?
|
| Monte Carlo Method | 2 | 2015 | 160 | 0.130 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3369 | 0.130 |
Why?
|
| Interdisciplinary Communication | 1 | 2015 | 207 | 0.130 |
Why?
|
| Pediatrics | 1 | 2022 | 1053 | 0.130 |
Why?
|
| Cause of Death | 1 | 2015 | 383 | 0.130 |
Why?
|
| Medicaid | 1 | 2017 | 373 | 0.130 |
Why?
|
| Social Media | 1 | 2016 | 142 | 0.130 |
Why?
|
| Disease Progression | 4 | 2021 | 2489 | 0.130 |
Why?
|
| Glycated Hemoglobin A | 1 | 2018 | 834 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2014 | 147 | 0.130 |
Why?
|
| Polymers | 1 | 2017 | 479 | 0.120 |
Why?
|
| Regional Health Planning | 1 | 2012 | 7 | 0.120 |
Why?
|
| Blood Pressure | 1 | 2020 | 1761 | 0.120 |
Why?
|
| Epinephrine | 1 | 2013 | 191 | 0.120 |
Why?
|
| Advanced Cardiac Life Support | 2 | 2022 | 25 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 1243 | 0.120 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 422 | 0.120 |
Why?
|
| Chest Wall Oscillation | 1 | 2011 | 5 | 0.120 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1432 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2017 | 969 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2016 | 693 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2021 | 798 | 0.110 |
Why?
|
| Multilingualism | 1 | 2011 | 27 | 0.110 |
Why?
|
| Body Mass Index | 2 | 2016 | 2098 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2021 | 2692 | 0.110 |
Why?
|
| Testosterone | 1 | 2013 | 307 | 0.110 |
Why?
|
| Peptides | 1 | 2016 | 884 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 750 | 0.100 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 2 | 2021 | 18 | 0.100 |
Why?
|
| Diuretics | 1 | 2009 | 84 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 641 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1302 | 0.100 |
Why?
|
| Multicenter Studies as Topic | 1 | 2009 | 222 | 0.100 |
Why?
|
| Comprehension | 1 | 2010 | 158 | 0.090 |
Why?
|
| Infusions, Intravenous | 1 | 2009 | 412 | 0.090 |
Why?
|
| Dabigatran | 2 | 2021 | 30 | 0.090 |
Why?
|
| Sex Factors | 3 | 2021 | 1997 | 0.090 |
Why?
|
| Propensity Score | 2 | 2021 | 226 | 0.090 |
Why?
|
| California | 2 | 2019 | 369 | 0.080 |
Why?
|
| Acute Disease | 1 | 2009 | 1000 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2011 | 728 | 0.080 |
Why?
|
| Infant, Newborn | 3 | 2022 | 5080 | 0.080 |
Why?
|
| Angina, Unstable | 2 | 2017 | 92 | 0.080 |
Why?
|
| Postoperative Care | 2 | 2017 | 233 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 872 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2487 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 2041 | 0.070 |
Why?
|
| Primary Health Care | 1 | 2015 | 1508 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 943 | 0.070 |
Why?
|
| Neoplasms | 1 | 2017 | 2037 | 0.070 |
Why?
|
| Adenoviridae Infections | 1 | 2002 | 8 | 0.060 |
Why?
|
| Thrombosis | 2 | 2016 | 265 | 0.060 |
Why?
|
| Adenoviruses, Human | 1 | 2002 | 28 | 0.060 |
Why?
|
| Stents | 2 | 2017 | 386 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2016 | 825 | 0.060 |
Why?
|
| Anesthesiologists | 1 | 2022 | 11 | 0.060 |
Why?
|
| Young Adult | 4 | 2021 | 10971 | 0.060 |
Why?
|
| Civil Defense | 1 | 2021 | 20 | 0.060 |
Why?
|
| Age Factors | 2 | 2021 | 3330 | 0.060 |
Why?
|
| Health Care Rationing | 1 | 2021 | 52 | 0.060 |
Why?
|
| Vital Signs | 1 | 2021 | 37 | 0.060 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 52 | 0.060 |
Why?
|
| Critical Pathways | 1 | 2021 | 63 | 0.060 |
Why?
|
| Thiazoles | 1 | 2021 | 123 | 0.050 |
Why?
|
| New York City | 1 | 2020 | 77 | 0.050 |
Why?
|
| Cholesterol | 1 | 2002 | 386 | 0.050 |
Why?
|
| Organ Size | 1 | 2021 | 499 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 89 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 75 | 0.050 |
Why?
|
| Dyspnea | 1 | 2021 | 186 | 0.050 |
Why?
|
| Pyridones | 1 | 2021 | 107 | 0.050 |
Why?
|
| Personal Protective Equipment | 1 | 2020 | 40 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2021 | 2380 | 0.050 |
Why?
|
| Rivaroxaban | 1 | 2021 | 183 | 0.050 |
Why?
|
| Data Collection | 2 | 2013 | 672 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2021 | 225 | 0.050 |
Why?
|
| Aorta, Thoracic | 1 | 2021 | 244 | 0.050 |
Why?
|
| Research Personnel | 1 | 2021 | 148 | 0.050 |
Why?
|
| Self Concept | 1 | 2021 | 227 | 0.050 |
Why?
|
| Aorta | 1 | 2021 | 410 | 0.050 |
Why?
|
| United Kingdom | 1 | 2019 | 246 | 0.050 |
Why?
|
| Prosthesis Implantation | 1 | 2019 | 117 | 0.050 |
Why?
|
| Minnesota | 1 | 2018 | 93 | 0.050 |
Why?
|
| Transitional Care | 1 | 2018 | 37 | 0.050 |
Why?
|
| Ventricular Flutter | 1 | 2017 | 1 | 0.050 |
Why?
|
| After-Hours Care | 1 | 2018 | 18 | 0.040 |
Why?
|
| Child | 3 | 2022 | 17711 | 0.040 |
Why?
|
| Population Growth | 1 | 2017 | 12 | 0.040 |
Why?
|
| Fractional Flow Reserve, Myocardial | 1 | 2017 | 11 | 0.040 |
Why?
|
| Consensus | 1 | 2020 | 427 | 0.040 |
Why?
|
| Punctures | 1 | 2017 | 40 | 0.040 |
Why?
|
| F Factor | 1 | 2017 | 5 | 0.040 |
Why?
|
| Atherosclerosis | 1 | 2021 | 306 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2018 | 130 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 522 | 0.040 |
Why?
|
| Pyrazoles | 1 | 2021 | 390 | 0.040 |
Why?
|
| Blood Circulation | 1 | 2017 | 36 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 483 | 0.040 |
Why?
|
| Angiography | 1 | 2017 | 158 | 0.040 |
Why?
|
| Critical Care | 1 | 2022 | 519 | 0.040 |
Why?
|
| Family Practice | 1 | 2021 | 479 | 0.040 |
Why?
|
| Europe | 1 | 2017 | 351 | 0.040 |
Why?
|
| Biomarkers | 2 | 2020 | 3501 | 0.040 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2017 | 153 | 0.040 |
Why?
|
| Information Storage and Retrieval | 1 | 2017 | 147 | 0.040 |
Why?
|
| Defibrillators | 1 | 2016 | 19 | 0.040 |
Why?
|
| Computers | 1 | 2016 | 70 | 0.040 |
Why?
|
| Ultrasonography, Interventional | 1 | 2017 | 133 | 0.040 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 121 | 0.040 |
Why?
|
| Ventricular Remodeling | 1 | 2018 | 215 | 0.040 |
Why?
|
| Tomography, Optical Coherence | 1 | 2017 | 138 | 0.040 |
Why?
|
| Health Personnel | 1 | 2021 | 485 | 0.040 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2016 | 55 | 0.040 |
Why?
|
| Research Report | 1 | 2016 | 76 | 0.040 |
Why?
|
| Public Health | 1 | 2020 | 422 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 2229 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 477 | 0.040 |
Why?
|
| Utilization Review | 1 | 2015 | 38 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 537 | 0.040 |
Why?
|
| Scientific Misconduct | 1 | 2015 | 11 | 0.040 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 42 | 0.040 |
Why?
|
| Risk-Taking | 1 | 2018 | 365 | 0.040 |
Why?
|
| Blood Transfusion | 1 | 2017 | 295 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 616 | 0.040 |
Why?
|
| Adolescent | 3 | 2021 | 18736 | 0.040 |
Why?
|
| Markov Chains | 1 | 2015 | 127 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2016 | 204 | 0.040 |
Why?
|
| Manikins | 1 | 2014 | 31 | 0.030 |
Why?
|
| Animals | 2 | 2015 | 35394 | 0.030 |
Why?
|
| Pressure | 1 | 2014 | 258 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2016 | 1004 | 0.030 |
Why?
|
| Mental Health | 1 | 2017 | 419 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 2016 | 1517 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2012 | 71 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1558 | 0.030 |
Why?
|
| Recurrence | 1 | 2015 | 967 | 0.030 |
Why?
|
| Palliative Care | 1 | 2018 | 631 | 0.030 |
Why?
|
| Hospital Administration | 1 | 2011 | 26 | 0.030 |
Why?
|
| Overweight | 1 | 2016 | 472 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2013 | 264 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2015 | 461 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3049 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 997 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2011 | 281 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2018 | 1940 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2011 | 1211 | 0.020 |
Why?
|
| Callitrichinae | 1 | 2002 | 1 | 0.020 |
Why?
|
| Macaca mulatta | 1 | 2002 | 163 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 402 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 2002 | 526 | 0.010 |
Why?
|
| Weight Gain | 1 | 2002 | 499 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2002 | 662 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 3910 | 0.010 |
Why?
|